Olfactory receptor as therapeutic target in bladder cancer

May 29, 2018

Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis. Using cell culture studies, the team headed by Prof Dr Dr Dr habil Hanns Hatt and Dr Lea Weber demonstrated that the receptor occurs more frequently in bladder cancer tissue than in healthy bladder tissue. Accordingly, significant higher amounts of the receptor could be found in the urine samples of patients. The team from the Department for Cellphysiology at Ruhr-Universität Bochum, together with colleagues from the Augusta Hospital in Bochum and the University Hospital in Düsseldorf, describes the results in the journal Frontiers in Physiology (May 16, 2018). The researchers, moreover, explain why the olfactory receptor might be a suitable therapeutic target in cancerous and other diseases of the urinary bladder.

Sandalwood aroma inhibits tumour growth

The olfactory receptor in bladder tissue is named OR10H1. The researchers from Bochum have demonstrated that it responds to sandalwood scents, for example Sandranol. In collaboration with Prof Dr Wolfgang Schulz from the University Hospital in Düsseldorf, they analysed the behaviour of cultivated cancer cells when OR10H1 is activated by Sandranol. Hatt and Weber, moreover, identified the signalling pathway that is switched on in the cell when the odorant binds with its receptor.

After application of Sandranol, as well as of Santanol, i.e. the main component of natural sandalwood oil, the bladder cancer cells altered their shape; they became rounder. Furthermore, cell division occurred less frequently and cell motility was poorer. "In our cell culture studies, we successfully inhibited tumour growth using sandalwood scent," says Hanns Hatt. This effect was amplified by the fact that receptor activation leads to the release of so-called interleukins as well as ATP, the molecular currency of energy transfer, thus switching on the immune system's natural killer cells in the tissue.

Detectable in urine

The team also analysed if the higher amount of receptors in bladder cancer tissue can be detected in urine. There, the researchers identified RNA transcripts of the receptors; they occurred in urine samples taken from bladder cancer patients in higher amounts than in healthy humans. "Consequently, OR10H1 might perhaps be used as biomarker for the diagnosis of bladder cancer with urine samples," concludes Director Dr Burkhard Ubrig from the Urology Clinic at the Augusta Hospital in Bochum.

Related study with breast cancer cells

In a related study, published in Frontiers in Oncology in February 2018, the cell physiologists from the Ruhr-Universität Bochum demonstrated that the OR2B6 olfactory receptor occurs exclusively in breast cancer tissue. It does not occur in healthy tissue; outside the nose, it can only be found in small amounts in lung and pancreatic cancer cells. Therefore, the OR2B6 olfactory receptor may be potentially suited as a specific biomarker for breast cancer diagnosis, according to the authors of the study.

"Both studies have confirmed previous research findings made in our lab, namely that olfactory receptors occur outside the nose in both healthy and diseased cells of the body and that particularly high amounts of such receptors can be found in tumour cells," says Hanns Hatt. "In future, they will play an important role not only in the diagnosis of diseases, but, first and foremost, they will provide novel approaches in tumour therapy."
-end-


Ruhr-University Bochum

Related Bladder Cancer Articles from Brightsurf:

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

Anthrax may be the next tool in the fight against bladder cancer
Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors.

Effectiveness of a new bladder cancer treatment demonstrated
Demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.

Lifting the lid on bladder cancer support
Bladder cancer is a painful and sometimes life-threatening condition that patients can find difficult to talk about, with many becoming homebound as they cope with debilitating side effects such as incontinence.

How genomics profiling can help identify the best treatment for bladder cancer
A new computational tool -- a single-patient classifier -- effectively enables physicians to assign a bladder cancer subtype to an individual patient's cancer using that patient's genomic data.

Early menopause in smokers linked to bladder cancer
Research shows that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer.

Olfactory receptor as therapeutic target in bladder cancer
Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis.

Bladder cancer model could pave the way for better drug efficacy studies
In the journal Cancer Research, UNC Lineberger Comprehensive Cancer Center researchers report they have developed a model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer.

Genetic fixer-uppers may help predict bladder cancer prognosis
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers, who found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer
Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.

Read More: Bladder Cancer News and Bladder Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.